There are several medications and medical devices coming soon that are in various stages of clinical trials, ranging from pre-clinical through to waiting for FDA approval or clearance. In addition to the trials listed below, there are several clinical trials investigating CGRP inhibitor medications in children and adolescents.
New FDA Approval!
- Zavegepant / Zavzpret™: Intranasal CGRP Receptor Agonist for abortive treatment of migraine. FDA Approval 3/10/23 and expected to be available for prescription in July 2023.
Phase II & III Clinical Trials
- Idebenone: An oral tablet which improves energy metabolism similar to CoQ10 and is being investigated for migraine prevention. (Currently in Phase 3 clinical trials)
- BIIB074/vixotrigine: A voltage- and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule. It is currently being studied in trigeminal neuralgia. (Phase 3 clinical trial set to start October 2021)
- Tricaprilin: An oral drug which has been designed to induce ketosis and improve mitochondrial metabolism, and is currently being investigated for preventive treatment of migraine. (Currently in Phase 2 clinical trials)
- Cannabis: Inhaled cannabis being investigated for acute treatment of migraine. (Currently in Phase 2 clinical trials)
- LY3451838: A PACAP inhibitor which is being investigated for preventive migraine treatment. (Currently recruiting for Phase 2 trials).
Pre-Clinical & Phase I Clinical Trials
- ALD1910: A PACAP inhibitor which is being investigated for preventive migraine treatment. (Currently finished a Phase 1 trial)
- Psilocybin: Oral psilocybin being investigated for preventive treatment of migraine. (Currently in Phase 1 clinical trials)
- XC101-D13H: A 5-HT2B/2C receptor antagonist without serotonergic agonist-driven side effects, which is currently being investigated for preventive treatment of migraine. (Currently in Phase 1 clinical trials)
- TRV250: Targeting the delta receptor, with potential to be a first-in-class, non-narcotic mechanism, this is being investigated for the acute treatment of migraine. (Currently in Phase 1 clinical trials)
Medical Devices in Clinical Trials
- Pulsante: Sphenopalatine Ganglion Stimulator. This device was FDA cleared April 2021 for the treatment of acute headache pain associated with chronic cluster headache. It is not yet FDA cleared for migraine in the USA, although it has received approval in Europe.
Download the Migraine Treatment Toolbox
Talk with your doctor to see if these options would be good to add to your treatment toolbox! Print out our Migraine Toolbox and bring it to your next appointment.